231 related articles for article (PubMed ID: 24378052)
1. Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Shen Y; Cai W; Lei S; Zhang Z
COPD; 2014 Jun; 11(3):351-8. PubMed ID: 24378052
[TBL] [Abstract][Full Text] [Related]
2. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review.
Fowdar K; Chen H; He Z; Zhang J; Zhong X; Zhang J; Li M; Bai J
Heart Lung; 2017; 46(2):120-128. PubMed ID: 28109565
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation.
Cazzola M; Calzetta L; Facciolo F; Rogliani P; Matera MG
Respir Res; 2017 Jan; 18(1):26. PubMed ID: 28118826
[TBL] [Abstract][Full Text] [Related]
4. Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes.
Zhang JQ; Zhang JQ; Liu H; Zhao ZH; Fang LZ; Liu L; Fu WP; Shu JK; Feng JG; Dai LM
Int J Chron Obstruct Pulmon Dis; 2015; 10():917-23. PubMed ID: 25999707
[TBL] [Abstract][Full Text] [Related]
5. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Xia QK; Gao Y; Zhong NS;
COPD; 2013 Apr; 10(2):164-71. PubMed ID: 23061828
[TBL] [Abstract][Full Text] [Related]
6. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
[TBL] [Abstract][Full Text] [Related]
7. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD.
Tse HN; Raiteri L; Wong KY; Ng LY; Yee KS; Tseng CZS
Chest; 2014 Sep; 146(3):611-623. PubMed ID: 24833327
[TBL] [Abstract][Full Text] [Related]
8. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.
Tse HN; Tseng CZ
Int J Chron Obstruct Pulmon Dis; 2014; 9():825-36. PubMed ID: 25125976
[TBL] [Abstract][Full Text] [Related]
9. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine.
van Overveld FJ; Demkow U; Górecka D; de Backer WA; Zielinski J
J Physiol Pharmacol; 2005 Sep; 56 Suppl 4():135-42. PubMed ID: 16204787
[TBL] [Abstract][Full Text] [Related]
10. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.
Decramer M; Rutten-van Mölken M; Dekhuijzen PN; Troosters T; van Herwaarden C; Pellegrino R; van Schayck CP; Olivieri D; Del Donno M; De Backer W; Lankhorst I; Ardia A
Lancet; 2005 Apr 30-May 6; 365(9470):1552-60. PubMed ID: 15866309
[TBL] [Abstract][Full Text] [Related]
11. Effect of oral N-acetylcysteine on COPD patients with microsatellite polymorphism in the heme oxygenase-1 gene promoter.
Zhang JQ; Zhang JQ; Fang LZ; Liu L; Fu WP; Dai LM
Drug Des Devel Ther; 2015; 9():6379-87. PubMed ID: 26674585
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of
Huang C; Kuo S; Lin L; Yang Y
Ther Adv Respir Dis; 2023; 17():17534666231158563. PubMed ID: 36927162
[TBL] [Abstract][Full Text] [Related]
13. High-dose N-acetylcysteine for long-term, regular treatment of early-stage chronic obstructive pulmonary disease (GOLD I-II): study protocol for a multicenter, double-blinded, parallel-group, randomized controlled trial in China.
Tian H; Zhou Y; Tang L; Wu F; Deng Z; Lin B; Huang P; Wei S; Zhao D; Zheng J; Zhong N; Ran P
Trials; 2020 Sep; 21(1):780. PubMed ID: 32917271
[TBL] [Abstract][Full Text] [Related]
14. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine.
Santus P; Corsico A; Solidoro P; Braido F; Di Marco F; Scichilone N
COPD; 2014 Dec; 11(6):705-17. PubMed ID: 24787454
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and meta-analysis of the efficacy of N-acetylcysteine in the treatment of acute exacerbation of chronic obstructive pulmonary disease.
Jiang C; Zou J; Lv Q; Yang Y
Ann Palliat Med; 2021 Jun; 10(6):6564-6576. PubMed ID: 34237968
[TBL] [Abstract][Full Text] [Related]
16. Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients.
De Backer J; Vos W; Van Holsbeke C; Vinchurkar S; Claes R; Parizel PM; De Backer W
Int J Chron Obstruct Pulmon Dis; 2013; 8():569-79. PubMed ID: 24293993
[TBL] [Abstract][Full Text] [Related]
17. N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation.
Calzetta L; Rogliani P; Facciolo F; Rinaldi B; Cazzola M; Matera MG
Biomed Pharmacother; 2018 Jul; 103():1-8. PubMed ID: 29635121
[TBL] [Abstract][Full Text] [Related]
18. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis.
Cazzola M; Calzetta L; Page C; Jardim J; Chuchalin AG; Rogliani P; Matera MG
Eur Respir Rev; 2015 Sep; 24(137):451-61. PubMed ID: 26324807
[TBL] [Abstract][Full Text] [Related]
19. N-acetylcysteine in patients with COPD exacerbations associated with increased sputum.
Ayfer Aytemur Z; Baysak A; Ozdemir O; Köse T; Sayiner A
Wien Klin Wochenschr; 2015 Apr; 127(7-8):256-61. PubMed ID: 25595117
[TBL] [Abstract][Full Text] [Related]
20. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial.
Johnson K; McEvoy CE; Naqvi S; Wendt C; Reilkoff RA; Kunisaki KM; Wetherbee EE; Nelson D; Tirouvanziam R; Niewoehner DE
Int J Chron Obstruct Pulmon Dis; 2016; 11():799-807. PubMed ID: 27143871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
